SIRPA and neoplasm: The combination of CD47 and PD-1 blocking antibodies results in a synergistic ability to inhibit tumor growth, providing a new strategy for immunotherapy.9 Recently, bispecific antibodies targeting PD-1-PD-L1 and CD47-SIRPα have also been applied in clinical trials as a new strategy.